Tokyo, May 13 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061522) titled 'Long-Term Follow-Up Analysis of a Phase II Study of Durvalumab Plus Concurrent Definitive Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer (WJOG11619L: DOLPHIN Study) (WJOG11619LFS)' on May 12.
Study Type:
Observational
Primary Sponsor:
Institute - West Japan Oncology Group
Condition:
Condition - Non-small cell lung cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - The objective is to evaluate the efficacy and safety of durvalumab in combination with definitive radiotherapy through long-term follow-up.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients enrolled in WJOG11619L who received at least one course of durvalumab (n=34) and did not meet any of the exclusion criteria will be included.
Key exclusion criteria - - Patients who have declined participation in this study through an opt-out process based on publicly available information
- Patients judged to be unsuitable for inclusion in this study by the principal investigator
Target Size - 34
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 04 Month 28 Day
Anticipated trial start date - 2026 Year 07 Month 01 Day
Last follow-up date - 2027 Year 08 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070400
Disclaimer: Curated by HT Syndication.
